Guided Therapeutics (GTHP) Cash from Operations (2016 - 2025)
Guided Therapeutics' Cash from Operations history spans 10 years, with the latest figure at 291000.0 for Q4 2025.
- On a quarterly basis, Cash from Operations rose 12.35% to 291000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 1068000.0, a 4.56% increase, with the full-year FY2025 number at 1068000.0, up 4.56% from a year prior.
- Cash from Operations hit 291000.0 in Q4 2025 for Guided Therapeutics, down from 277000.0 in the prior quarter.
- Over the last five years, Cash from Operations for GTHP hit a ceiling of 159000.0 in Q4 2021 and a floor of 739000.0 in Q3 2021.
- Historically, Cash from Operations has averaged 350200.0 across 5 years, with a median of 334000.0 in 2023.
- Biggest five-year swings in Cash from Operations: skyrocketed 148.04% in 2021 and later crashed 313.21% in 2022.
- Tracing GTHP's Cash from Operations over 5 years: stood at 159000.0 in 2021, then tumbled by 313.21% to 339000.0 in 2022, then rose by 0.88% to 336000.0 in 2023, then grew by 1.19% to 332000.0 in 2024, then increased by 12.35% to 291000.0 in 2025.
- Business Quant data shows Cash from Operations for GTHP at 291000.0 in Q4 2025, 277000.0 in Q3 2025, and 169000.0 in Q2 2025.